Overview
BDTX market data
Price History
BDTX price chart
Valuation & Profitability
- P/E (TTM)
- 4.69 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.39 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.60 – $4.94 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $104.9 · P/B 1.23.
Company news
What's Going On With Black Diamond Therapeutics Stock Tuesday?Benzinga · May 26, 2026, 4:15 PM
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceGlobenewswire Inc · May 22, 2026, 12:15 PM
Black Diamond Therapeutics' Silevertinib Shows 15.2-Month Median PFS And 60% Response Rate With CNS Activity In EGFR Non-Classical Mutation NSCLC Phase 2 StudyBenzinga · May 21, 2026, 9:20 PM
8-K filing — Black Diamond Therapeutics, Inc. (BDTX)SEC EDGAR · May 21, 2026, 9:19 PM
Black Diamond Therapeutics To Host Webcast For Investors To Present Updated Results From Ongoing Phase 2 Trial Of Silevertinib In Frontline Patients With EGFR Mutated Non-Small Cell Lung Cancer On May 21Benzinga · May 19, 2026, 12:10 PM